Brief: Zura Bio Completes Approximately $80 Million Financing With The Focus On Advancing Zb-106, A Potential First-In-Class Anti-Il-17 And Anti-Baff Dual Antagonist
06/06/2023 09:02
June 6 (Reuters) - Zura Bio Ltd ZURA.O :
* ZURA BIO COMPLETES APPROXIMATELY $80 MILLION FINANCING
WITH THE
FOCUS ON ADVANCING ZB-106, A POTENTIAL FIRST-IN-CLASS ANTI-IL-17
AND ANTI-BAFF DUAL ANTAGONIST
Source text for Eikon: ID:nBw7PQxhDa
Further company coverage: ZURA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zura Bio
See all newsZura Bio Ltd reports results for the quarter ended June 30 - Earnings Summary
Zura Bio Q2 net loss widens as R&D expenses rise
Zura Bio Ltd expected to post a loss of 20 cents a share - Earnings Preview
Brief: Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Zura Bio Expands Leadership Team With Appointment Of Muzammil Mustufa As Chief Business Officer